Personal information

Other IDs

Scopus Author ID: 6603325754

Keywords

Melanoma, skin cancer, clinical trial immunetherapy, target therapies, drug development

Countries

Spain

Activities

Collapse all

Employment (8)

University of Barcelona: Barcelona, ES

2009 to present (Clinical Professor in Medical Oncology,)
Employment
Source: Self-asserted source
Ana Arance

Hospital Clinic of Barcelona: Barcelona, ES

2009 to present (Oncology Department)
Employment
Source: Self-asserted source
Ana Arance

Universitat Autònoma de Barcelona: Barcelona, ES

2008 to 2009 (Associate Professor)
Employment
Source: Self-asserted source
Ana Arance

Hospital de Mataró: Barcelona, ES

2004 to 2007 (Specialist in Medical Oncology)
Employment
Source: Self-asserted source
Ana Arance

Hammersmith Hospital: Londres, GB

2004 to 2007 | Associate Specialist Oncology (Medical Oncology)
Employment
Source: Self-asserted source
Ana Arance

MRC Clinical SCI Centre: Londres, GB

2001 to 2004 (Clinical Investigator)
Employment
Source: Self-asserted source
Ana Arance

Christie Hospital: Manchester, GB

1999 to 2001 (Associate Specialist)
Employment
Source: Self-asserted source
Ana Arance

Instituto Catala Oncologico: Barcelona, ES

1995 to 1998 | Resident in Medical Oncology (Medical Oncology)
Employment
Source: Self-asserted source
Ana Arance

Education and qualifications (5)

Institut Català d'Oncologia: Barcelona, ES

(Specialist in Medical Oncology)
Qualification
Source: Self-asserted source
Ana Arance

Estudio del valor pronóstico de los receptores de quimiocinas en pacientes con melanoma maligno primario: Madrid, ES

2010 to 2013 (Fundación Mutua Madrileña)
Qualification
Source: Self-asserted source
Ana Arance

Imperial College London: London, London, GB

2005 | Phd (Doctor in Philosophy)
Qualification
Source: Self-asserted source
Ana Arance

University of Manchester: Manchester, IA, ES

2002 (MD (Doctor in Medicine))
Qualification
Source: Self-asserted source
Ana Arance

University of Barcelona: Barcelona, ES

1987 | Bachelor of Medicine and Surgery (Medicine and Surgery)
Qualification
Source: Self-asserted source
Ana Arance

Professional activities (6)

GETICA (Grupo Español de Terapias Immuno-Biológicas en Cáncer: Madrid, ES

2021-01-01 to present | Presidenta
Membership
Source: Self-asserted source
Ana Arance

GRUPO ESPAÑOL MULTIDISCIPLINAR DE MELANOMA: VALENCIA, ES

2020 to present | President
Service
Source: Self-asserted source
Ana Arance

European Society for Medical Oncology: Lugano, CH

2019 to present | Member of the Scientific Committee
Service
Source: Self-asserted source
Ana Arance

Sociedad Española de Oncología Médica: Madrid, ES

2017 to present
Service
Source: Self-asserted source
Ana Arance

SPANISH GROUP FOR CANCER IMMUNO-BIOTHERAPY: VALENCIA, ES

2016 to 2020 | Member of the Scientific Spanish Group for Immunotherapy
Service
Source: Self-asserted source
Ana Arance

Grupo Español Multidisciplinar de Melanoma: Barcelona, ES

2012 to 2018 (Member of the Scientific Committee of the Spanish Melanoma Group)
Service
Source: Self-asserted source
Ana Arance

Funding (2)

Identificación y validación de una firma genómica predictiva de beneficio a fármacos anti-PD1 en múltiples tumores sólidos

2016 to 2019 | Award
Beca FSEOM 40 Aniversario para Proyectos de Investigación en Inmuno-Oncología (madrid, ES)
Source: Self-asserted source
Ana Arance

Inflamación y cáncer de mama: influencia neuronal y de neuropéptidos pro-inflamatorios en la progresión tumoral a través de la modulación del fenotipo de la célula madre

2013 to 2015 | Award
Instituto de Salud Carlos III (Madrid, ES)
Source: Self-asserted source
Ana Arance

Peer review (10 reviews for 4 publications/grants)

Review activity for Communications medicine. (1)
Review activity for European journal of cancer. (6)
Review activity for International journal of dermatology. (1)
Review activity for Journal for immunotherapy of cancer. (2)
How many people are using ORCID?